The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

Advances in Treatment of Locally Advanced or Metastatic Non–Small

Clinical and Translational Implications of RET Rearrangements in

Recombinant Anti-LTK antibody [EPR5175(2)] (ab129155)

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - Sentana-Lledo - Translational Lung Cancer Research

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung

Biological and clinical perspectives of the actionable gene

Clinical application of the AMOY 9-in-1 panel to lung cancer

Combinatorial tumor suppressor inactivation efficiently initiates

ROS1-dependent cancers - biology, diagnostics and therapeutics